KEGG   PATHWAY: cjc05235
Entry
cjc05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Callithrix jacchus (white-tufted-ear marmoset)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
cjc05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
cjc05235

Organism
Callithrix jacchus (white-tufted-ear marmoset) [GN:cjc]
Gene
100411678  HIF1A; hypoxia-inducible factor 1-alpha isoform X1 [KO:K08268]
100388651  EGF; pro-epidermal growth factor isoform X1 [KO:K04357]
100412158  EGFR; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
100406017  HRAS; GTPase HRas [KO:K02833]
118144179  KRAS; GTPase KRas isoform X2 [KO:K07827]
100414782  NRAS; GTPase NRas isoform X2 [KO:K07828]
108591807  GTPase NRas-like [KO:K07828]
100415300  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
100387394  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 isoform X1 [KO:K04368] [EC:2.7.12.2]
100393991  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
100400700  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
100404815  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
100390054  FOS; protein c-Fos [KO:K04379]
100400411  JUN; transcription factor Jun [KO:K04448]
100410033  EML4; echinoderm microtubule-associated protein-like 4 isoform X2 [KO:K15420]
100399252  ALK; ALK tyrosine kinase receptor isoform X1 [KO:K05119] [EC:2.7.10.1]
100406689  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
100392639  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X2 [KO:K02649]
100414659  PIK3R3; phosphatidylinositol 3-kinase regulatory subunit gamma isoform X2 [KO:K02649]
100403494  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
100391655  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform isoform X2 [KO:K00922] [EC:2.7.1.153]
100398849  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
100393460  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
100404447  AKT1; RAC-alpha serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
100399039  AKT3; RAC-gamma serine/threonine-protein kinase isoform X6 [KO:K04456] [EC:2.7.11.1]
100388080  AKT2; RAC-beta serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
100406608  MTOR; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
100397180  RPS6KB2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
100409247  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X3 [KO:K04688] [EC:2.7.11.1]
100393096  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X2 [KO:K07209] [EC:2.7.11.10]
100390258  IKBKG; NF-kappa-B essential modulator isoform X1 [KO:K07210]
100402266  NFKBIA; NF-kappa-B inhibitor alpha [KO:K04734]
100408512  NFKBIB; NF-kappa-B inhibitor beta isoform X1 [KO:K02581]
100393268  NFKBIE; NF-kappa-B inhibitor epsilon [KO:K05872]
100415321  NFKB1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580]
100388493  RELA; transcription factor p65 isoform X1 [KO:K04735]
100388952  IFNG; interferon gamma precursor [KO:K04687]
100386516  IFNGR1; interferon gamma receptor 1 isoform X1 [KO:K05132]
100389763  IFNGR2; interferon gamma receptor 2 [KO:K05133]
100385835  JAK1; tyrosine-protein kinase JAK1 isoform X1 [KO:K11217] [EC:2.7.10.2]
100413251  JAK2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
100401630  STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
100389282  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
100404611  TLR2; toll-like receptor 2 [KO:K10159]
100399012  TLR4; toll-like receptor 4 isoform X1 [KO:K10160]
100411708  TLR9; toll-like receptor 9 isoform X2 [KO:K10161]
100409771  TIRAP; toll/interleukin-1 receptor domain-containing adapter protein isoform X1 [KO:K05403]
100413151  MYD88; myeloid differentiation primary response protein MyD88 isoform X1 [KO:K04729]
100395364  TRAF6; TNF receptor-associated factor 6 isoform X2 [KO:K03175] [EC:2.3.2.27]
100405187  NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X2 [KO:K04446]
100414856  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
100406801  NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
100405343  TICAM1; TIR domain-containing adapter molecule 1 [KO:K05842]
100409449  TICAM2; TIR domain-containing adapter molecule 2 [KO:K05409]
100415050  CD274; programmed cell death 1 ligand 1 precursor [KO:K06745]
100400173  PDCD1; programmed cell death protein 1 isoform X1 [KO:K06744]
100410231  PTPN6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
100414905  PTPN11; tyrosine-protein phosphatase non-receptor type 11 isoform X3 [KO:K07293] [EC:3.1.3.48]
100391373  BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
100408449  BATF2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034]
118149480  BATF3; basic leucine zipper transcriptional factor ATF-like 3 [KO:K09034]
100414021  CSNK2A1; LOW QUALITY PROTEIN: casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
100388528  CSNK2A2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
100895978  LOW QUALITY PROTEIN: casein kinase II subunit beta [KO:K03115]
100401722  CSNK2B; casein kinase II subunit beta isoform X1 [KO:K03115]
100385000  CD4; T-cell surface glycoprotein CD4 precursor [KO:K06454]
100410584  LCK; tyrosine-protein kinase Lck isoform X1 [KO:K05856] [EC:2.7.10.2]
100403944  CD3E; T-cell surface glycoprotein CD3 epsilon chain precursor [KO:K06451]
100404679  T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
100409044  T cell receptor alpha variable 8-6 [KO:K10784]
100896987  T cell receptor beta variable 7-2 [KO:K10785]
100896470  T cell receptor beta variable 7-9 [KO:K10785]
100896810  CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
100404313  CD3D; T-cell surface glycoprotein CD3 delta chain isoform X2 [KO:K06450]
100390922  tyrosine-protein kinase ZAP-70 isoform X2 [KO:K07360] [EC:2.7.10.2]
100409608  MAP3K3; mitogen-activated protein kinase kinase kinase 3 isoform X1 [KO:K04421] [EC:2.7.11.25]
100398593  MAP2K3; dual specificity mitogen-activated protein kinase kinase 3 isoform X2 [KO:K04432] [EC:2.7.12.2]
100397389  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 isoform X3 [KO:K04433] [EC:2.7.12.2]
100396611  MAPK11; mitogen-activated protein kinase 11 [KO:K04441] [EC:2.7.11.24]
100396967  MAPK12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
100404377  MAPK14; mitogen-activated protein kinase 14 isoform X2 [KO:K04441] [EC:2.7.11.24]
100405093  MAPK13; mitogen-activated protein kinase 13 isoform X1 [KO:K04441] [EC:2.7.11.24]
100414442  LAT; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
100397497  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 [KO:K01116] [EC:3.1.4.11]
100386369  PPP3CA; protein phosphatase 3 catalytic subunit alpha isoform X1 [KO:K04348] [EC:3.1.3.16]
100387059  PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X4 [KO:K04348] [EC:3.1.3.16]
100386452  PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X5 [KO:K04348] [EC:3.1.3.16]
100392986  PPP3R2; calcineurin subunit B type 2 [KO:K06268]
100388148  PPP3R1; calcineurin subunit B type 1 [KO:K06268]
100390905  RASGRP1; RAS guanyl-releasing protein 1 isoform X1 [KO:K04350]
100408536  CD28; T-cell-specific surface glycoprotein CD28 precursor [KO:K06470]
100415241  PRKCQ; protein kinase C theta type isoform X2 [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
cjc04010  MAPK signaling pathway
cjc04020  Calcium signaling pathway
cjc04066  HIF-1 signaling pathway
cjc04151  PI3K-Akt signaling pathway
cjc04514  Cell adhesion molecules
cjc04620  Toll-like receptor signaling pathway
cjc04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system